The effect of intensive inpatient rehabilitation after botulinum toxin type A administration for patients with chronic motor paralysis after stroke

The effect of intensive inpatient rehabilitation after botulinum toxin type A administration for patients with chronic motor paralysis after stroke - The effect of intensive inpatient rehabilitation after botulinum toxin type A administration

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053225

Enrollment

Registered

2024-01-01

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient with chronic motor paralysis after stroke

Interventions

1) Botulinum toxin A (BoNT-A) therapy Total dosage 400 units or less 2) Intensive rehabilitation Intensive rehabilitation will be performed daily, 120 minutes/day for 28 days. The program&#39

s contents are KINVIS therapy (20 minutes) and individual rehabilitation (100 minutes). 1) Botulinum toxin A (BoNT-A) therapy Total dosage 400 units or less 2) Intensive rehabilitation Intensi

s content is individual rehabilitation (120 minutes). 1) Botulinum toxin A (BoNT-A) therapy Total dosage 400 units or less 2) Intensive rehabilitation Intensive rehabilitation will be performed

s contents are KINVIS therapy (20 minutes) and individual rehabilitation (100 minutes). 1) Botulinum toxin A (BoNT-A) therapy Total dosage 400 units or less 2) Intensive rehabilitation Intensiv

s content is individual rehabilitation (120 minutes).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients in the chronic phase of stroke who are visiting our outpatient clinic and whose Modified Ashworth Scale (MAS) score of the target spastic muscle is between 1+ (mild hypertonia with resistance less than 1/2 the range of motion) and less than 4 (affected area is rigid and difficult to flex and extend), without significant cognitive dysfunction (Mini-Mental State Examination; MSE 24 points or higher).

Exclusion criteria

Exclusion criteria: Patients treated for spasticity with oral muscle relaxants, motor point block with phenol, intrathecal baclofen pump therapy within the last three months

Design outcomes

Primary

Measure	Time frame
Modified Ashworth Scale measured 4 and 8 weeks after administration of botulinum toxin type A	—

Secondary

Measure	Time frame
Global Rating of Change scale, Fugl-Meyer Assessment, Action Research Arm Test, Box and Block Test, Motor Activity Log, 10m walk test, Euro Qol-5D	—

Countries

Japan

Contacts

Public ContactSho Maruyama

Shonan-Keiiku Hospital Department of Rehabilitation

s-maruyama@keiiku.gr.jp0466480050

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026